Janux Therapeutics, Inc. (JANX)
- Business Wire
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
SAN DIEGO, November 09, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021.
- Business Wire
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
SAN DIEGO, November 08, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences:
- Simply Wall St.
Insiders at Janux Therapeutics, Inc. (NASDAQ:JANX) snagged a bargain: a US$631k profit on a US$1m buy
Insiders who bought Janux Therapeutics, Inc. ( NASDAQ:JANX ) stock lover the last 12 months are probably not as...
